Publications

Cancer research

Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence.

01-06-2026

Nature

Tumour-reactive heterotypic CD8 T cell clusters from clinical samples.

01-01-2026

Journal for immunotherapy of cancer

Categorizing immunotherapy resistance mechanisms in non-small cell lung cancer: how can we perform better?

28-11-2025

Cell death discovery

Inhibition of TBK1/IKKε mediated RIPK1 phosphorylation sensitizes tumors to immune cell killing.

28-11-2025

Nature genetics

Cytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal-like cancers.

01-07-2025

Pharmacological research

Resistance to BRAF inhibitors drives melanoma sensitivity to Chk1 inhibition.

01-07-2025

Cell death & disease

TRAF2 and RIPK1 redundantly mediate classical NFκB signaling by TNFR1 and CD95-type death receptors.

21-01-2025

Nucleic acids research

Chemotherapeutic agents and leucine deprivation induce codon-biased aberrant protein production in cancer.

11-12-2024

Journal for immunotherapy of cancer

TMED inhibition suppresses cell surface PD-1 expression and overcomes T cell dysfunction.

07-11-2024

Nature reviews. Cancer

Rational combination of cancer therapies with PD1 axis blockade.

30-07-2024

Cancer cell

Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness.

08-04-2024

Cell reports

Phosphoprotein dynamics of interacting T cells and tumor cells by HySic.

23-01-2024

Frontiers in immunology

Heterogeneity in functional genetic screens: friend or foe?

03-07-2023

European journal of immunology

Acidity-mediated induction of FoxP3⁺ regulatory T cells.

01-06-2023

Molecular cancer research : MCR

The Elongin BC Complex Negatively Regulates AXL and Marks a Differentiated Phenotype in Melanoma.

01-05-2023

The Journal of experimental medicine

IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma.

01-05-2023

Cancer immunology research

Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells.

03-04-2023

The EMBO journal

TSC2 regulates tumor susceptibility to TRAIL-mediated T-cell killing by orchestrating mTOR signaling.

01-03-2023

Cell reports. Medicine

An adverse tumor-protective effect of IDO1 inhibition.

21-02-2023

Nature communications

Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.

07-02-2023

Melanoma research

MeVa2.1.dOVA and MeVa2.2.dOVA: two novel BRAFV600E-driven mouse melanoma cell lines to study tumor immune resistance.

01-02-2023

Oncoimmunology

SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response.

06-12-2022

Nature

Author Correction: Tryptophan depletion results in tryptophan-to-phenylalanine substitutants.

01-08-2022

Cell reports. Medicine

RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells.

21-06-2022

Nature communications

Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling.

08-04-2022

Key Publication

Cancer discovery

Plasticity of Extrachromosomal and Intrachromosomal BRAF Amplifications in Overcoming Targeted Therapy Dosage Challenges.

01-04-2022

Nature

Tryptophan depletion results in tryptophan-to-phenylalanine substitutants.

01-03-2022

Nature communications

Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.

22-12-2021

Molecular cell

Oncogene-dependent sloppiness in mRNA translation.

18-11-2021

Immuno-oncology technology

The (re)discovery of tumor-intrinsic determinants of immune sensitivity by functional genetic screens.

01-10-2021

Clinical cancer research : an official journal of the American Association for Cancer Research

Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4.

01-10-2021

Science (New York, N.Y.)

Enabling oncogenes.

03-09-2021

Journal of proteome research

Proteomics and Phosphoproteomics Profiling of Drug-Addicted BRAFi-Resistant Melanoma Cells.

03-09-2021

Cancer immunology, immunotherapy : CII

Metabolic profiles of regulatory T cells in the tumour microenvironment.

01-09-2021

Cancer research

Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody-Drug Conjugate and Immune Checkpoint Blockade.

01-04-2021

Nature

Anti-tumour immunity induces aberrant peptide presentation in melanoma.

01-02-2021

Nature medicine

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.

01-02-2021

Journal for immunotherapy of cancer

Comprehensive analysis of cutaneous and uveal melanoma liver metastases.

01-12-2020

Nature communications

Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.

07-08-2020

Journal of translational medicine

Presence of a 34-gene signature is a favorable prognostic marker in squamous non-small cell lung carcinoma.

03-07-2020

Molecular cell

Rational Cancer Treatment Combinations: An Urgent Clinical Need.

18-06-2020

The Journal of experimental medicine

Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice.

01-06-2020

Science (New York, N.Y.)

The human tumor microbiome is composed of tumor type-specific intracellular bacteria.

29-05-2020

Cell reports

FGFR1 Oncogenic Activation Reveals an Alternative Cell of Origin of SCLC in Rb1/p53 Mice.

17-03-2020

Pigment cell & melanoma research

A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanoma.

01-03-2020

Molecular & cellular proteomics : MCP

Combined EGFR and ROCK Inhibition in Triple-negative Breast Cancer Leads to Cell Death Via Impaired Autophagic Flux.

01-02-2020

Nature

B cells and tertiary lymphoid structures promote immunotherapy response.

01-01-2020

Cell systems

High-Throughput Assessment of Kinome-wide Activation States.

23-10-2019

Molecular cancer therapeutics

In Vivo ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in Melanoma.

01-09-2019

Cell

Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold.

25-07-2019

Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence.

Tumour-reactive heterotypic CD8 T cell clusters from clinical samples.

Categorizing immunotherapy resistance mechanisms in non-small cell lung cancer: how can we perform better?

Inhibition of TBK1/IKKε mediated RIPK1 phosphorylation sensitizes tumors to immune cell killing.

Cytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal-like cancers.

Resistance to BRAF inhibitors drives melanoma sensitivity to Chk1 inhibition.

TRAF2 and RIPK1 redundantly mediate classical NFκB signaling by TNFR1 and CD95-type death receptors.

Chemotherapeutic agents and leucine deprivation induce codon-biased aberrant protein production in cancer.

TMED inhibition suppresses cell surface PD-1 expression and overcomes T cell dysfunction.

Rational combination of cancer therapies with PD1 axis blockade.

Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness.

Phosphoprotein dynamics of interacting T cells and tumor cells by HySic.

Heterogeneity in functional genetic screens: friend or foe?

Acidity-mediated induction of FoxP3+ regulatory T cells.

The Elongin BC Complex Negatively Regulates AXL and Marks a Differentiated Phenotype in Melanoma.

IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma.

Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells.

TSC2 regulates tumor susceptibility to TRAIL-mediated T-cell killing by orchestrating mTOR signaling.

An adverse tumor-protective effect of IDO1 inhibition.

Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.

MeVa2.1.dOVA and MeVa2.2.dOVA: two novel BRAFV600E-driven mouse melanoma cell lines to study tumor immune resistance.

SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response.

Author Correction: Tryptophan depletion results in tryptophan-to-phenylalanine substitutants.

RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells.

Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling.

Plasticity of Extrachromosomal and Intrachromosomal BRAF Amplifications in Overcoming Targeted Therapy Dosage Challenges.

Tryptophan depletion results in tryptophan-to-phenylalanine substitutants.

Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.

Oncogene-dependent sloppiness in mRNA translation.

The (re)discovery of tumor-intrinsic determinants of immune sensitivity by functional genetic screens.

Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4.

Enabling oncogenes.

Proteomics and Phosphoproteomics Profiling of Drug-Addicted BRAFi-Resistant Melanoma Cells.

Metabolic profiles of regulatory T cells in the tumour microenvironment.

Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody-Drug Conjugate and Immune Checkpoint Blockade.

Anti-tumour immunity induces aberrant peptide presentation in melanoma.

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.

Comprehensive analysis of cutaneous and uveal melanoma liver metastases.

Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.

Presence of a 34-gene signature is a favorable prognostic marker in squamous non-small cell lung carcinoma.

Rational Cancer Treatment Combinations: An Urgent Clinical Need.

Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice.

The human tumor microbiome is composed of tumor type-specific intracellular bacteria.

FGFR1 Oncogenic Activation Reveals an Alternative Cell of Origin of SCLC in Rb1/p53 Mice.

A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanoma.

Combined EGFR and ROCK Inhibition in Triple-negative Breast Cancer Leads to Cell Death Via Impaired Autophagic Flux.

B cells and tertiary lymphoid structures promote immunotherapy response.

High-Throughput Assessment of Kinome-wide Activation States.

In Vivo ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in Melanoma.

Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold.

This site uses cookies

Acidity-mediated induction of FoxP3⁺ regulatory T cells.